These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 36226398

  • 1. [Apalutamide, Erleada®].
    Sautois B, Denis C.
    Rev Med Liege; 2022 Oct; 77(10):609-615. PubMed ID: 36226398
    [Abstract] [Full Text] [Related]

  • 2. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
    Ming J, Wu Y, Han R, Xu X, Waldeck R, Hu S.
    Adv Ther; 2023 Mar; 40(3):1087-1103. PubMed ID: 36630046
    [Abstract] [Full Text] [Related]

  • 3. Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
    Saad F, Small EJ, Feng FY, Graff JN, Olmos D, Hadaschik BA, Oudard S, Londhe A, Bhaumik A, Lopez-Gitlitz A, Thomas S, Mundle SD, Chowdhury S, Smith MR.
    Eur Urol; 2022 Feb; 81(2):184-192. PubMed ID: 34916086
    [Abstract] [Full Text] [Related]

  • 4. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
    Chowdhury S, Oudard S, Uemura H, Joniau S, Dearden L, Capone C, Van Sanden S, Diels J, Hadaschik BA.
    Adv Ther; 2022 Jan; 39(1):518-531. PubMed ID: 34797506
    [Abstract] [Full Text] [Related]

  • 5. Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy.
    Oudard S, Hadaschik B, Saad F, Cella D, Basch E, Graff JN, Uemura H, Dibaj S, Li S, Brookman-May SD, De Porre P, Bevans KB, Trudeau JJ, Small EJ, Smith MR.
    Eur Urol Focus; 2022 Jul; 8(4):958-967. PubMed ID: 34479838
    [Abstract] [Full Text] [Related]

  • 6. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C, Abboud K.
    Am J Health Syst Pharm; 2022 Jul 22; 79(15):1224-1235. PubMed ID: 35390118
    [Abstract] [Full Text] [Related]

  • 7. Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.
    Al-Salama ZT.
    Drugs; 2019 Sep 22; 79(14):1591-1598. PubMed ID: 31489589
    [Abstract] [Full Text] [Related]

  • 8. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).
    Aggarwal R, Heller G, Hillman DW, Xiao H, Picus J, Taplin ME, Dorff T, Appleman L, Weckstein D, Patnaik A, Bryce A, Shevrin D, Mohler J, Anderson D, Rao A, Tagawa S, Tan A, Halabi S, Dooley K, O'Brien P, Chen R, Ryan CJ, Eggener SE, Morris MJ, EORTC-55994 Study Group.
    J Clin Oncol; 2024 Apr 01; 42(10):1114-1123. PubMed ID: 38261983
    [Abstract] [Full Text] [Related]

  • 9. Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions.
    Conde-Estévez D, Henríquez I, Muñoz-Rodríguez J, Rodriguez-Vida A.
    Expert Opin Drug Metab Toxicol; 2022 Sep 01; 18(9):601-613. PubMed ID: 36111393
    [Abstract] [Full Text] [Related]

  • 10. Apalutamide for the treatment of patients with castration-resistant prostate cancer.
    Hauke R.
    Drugs Today (Barc); 2018 Oct 01; 54(10):585-590. PubMed ID: 30398479
    [Abstract] [Full Text] [Related]

  • 11. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
    Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R, de Boer CJ, Yu MK, Rathkopf DE.
    Eur Urol; 2016 Dec 01; 70(6):963-970. PubMed ID: 27160947
    [Abstract] [Full Text] [Related]

  • 12. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
    Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, Özgüroğlu M, Juárez Soto Á, Merseburger AS, Uemura H, Ye D, Given R, Cella D, Basch E, Miladinovic B, Dearden L, Deprince K, Naini V, Lopez-Gitlitz A, Chi KN, TITAN investigators.
    Lancet Oncol; 2019 Nov 01; 20(11):1518-1530. PubMed ID: 31578173
    [Abstract] [Full Text] [Related]

  • 13. Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer.
    Small EJ, Chi KN, Chowdhury S, Bevans KB, Bhaumik A, Saad F, Chung BH, Karsh LI, Oudard S, De Porre P, Brookman-May SD, McCarthy SA, Mundle SD, Uemura H, Smith MR, Agarwal N.
    Eur Urol Oncol; 2024 Aug 01; 7(4):844-852. PubMed ID: 38072759
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada.
    Saad F, Chilelli A, Hui B, Muratov S, Ganguli A, North S, Shayegan B.
    J Med Econ; 2022 Aug 01; 25(1):583-590. PubMed ID: 35469527
    [Abstract] [Full Text] [Related]

  • 15. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.
    Eur Urol; 2018 May 01; 73(5):696-703. PubMed ID: 29074061
    [Abstract] [Full Text] [Related]

  • 16. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Kluth LA, Briganti A, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI.
    Prostate Cancer Prostatic Dis; 2022 Feb 01; 25(2):139-148. PubMed ID: 34054128
    [Abstract] [Full Text] [Related]

  • 17. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Ladouceur M, Behl AS, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA.
    Adv Ther; 2020 Jan 01; 37(1):501-511. PubMed ID: 31813086
    [Abstract] [Full Text] [Related]

  • 18. Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study.
    Hegele A, Häußermann R, Schultheis S, Skrobek L, Vink M, Hollwegs S, Ludwig M, Huwe P, Maywurm M, Bartsch-Polle A, Weber J, Thiemer M, Varughese D.
    J Cancer Res Clin Oncol; 2024 Sep 09; 150(9):414. PubMed ID: 39249593
    [Abstract] [Full Text] [Related]

  • 19. Role of apalutamide in the treatment landscape for patients with advanced prostate cancer: an expert opinion statement of European clinical practice.
    Bögemann M, Facchini G, Bauernhofer T, Cathomas R, Xylinas E, Tombal B.
    Ir J Med Sci; 2023 Dec 09; 192(6):2643-2651. PubMed ID: 36944842
    [Abstract] [Full Text] [Related]

  • 20. Treatment and trials in non-metastatic castration-resistant prostate cancer.
    Lokeshwar SD, Klaassen Z, Saad F.
    Nat Rev Urol; 2021 Jul 09; 18(7):433-442. PubMed ID: 34002069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.